ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 41 | October 25, 1985

Download PDF Visit The Full Archive

Related Articles

J&J, Amgen Settle Lawsuit Over ESAs As FDA Prepares Another Label Change.

July 18, 2008

Treat Cancer, But Protect Heart Anderson Cardiologists Warn

July 30, 2004

In Brief: FCRC Committee Loses Chance To influence RFP; Recompetition To Remain On Schedule

November 5, 1976

Patient Advocacy: Breast Cancer Coalition Forms PAC To Increase Political Activities

April 18, 1997

Novel Antifungal Agent Highly Active Against Esophageal Candidiasis

October 31, 2003

GAO Suggests No Limit On Indirect Costs But Ceiling On Total Costs

September 7, 1979